A randomised double-blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Brief Description Of Study

This study is designed to test the hypothesis that ticagrelor monotherapy when compared with clopidogrel monotherapy will reduce the incidence of atherothrombotic ischaemic events, as measured by the composite of CV death, MI, and ischaemic stroke in patients with established PAD. Patients will receive either 90 mg ticagrelor orally bd and clopidogrel placebo in the morning, or 75 mg clopidogrel od (morning) and ticagrelor placebo bd. The patients will be followed for an anticipated minimum of 18 months and up to approximately 36 months.

Clinical Study Identifier: 817042

Contact research investigator to learn more about this study by filling out the form below.


To: Research Study Investigator
Subject: I am interested in participating in your Research Study
Dear Investigator,
I'm interested in learning more about and participating in your research study named: A randomised double-blind parallel group multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
I am hoping to hear back from you and discuss details of the study

By clicking "Contact Research Team", your contact information will be sent directly to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.